Fig. 6From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trialsMean change from baseline in MSQoL in participants with (a) EMa and (b) CMb. CM, chronic migraine; EM, episodic migraine; MAMD, monthly average migraine days; MSQoL, Migraine-Specific Quality of Life; MSQoL-EF, MSQoL emotional function; MSQoL-RFR, MSQoL role function–restrictive; MSQoL-RFP, MSQoL role function–preventive; SE, standard error. aFor participants with EM, response was defined as a reduction of ≥ 2 MAMD. bFor participants with CM, response was defined as a reduction of ≥ 4 MAMDBack to article page